A controlled clinical trial to evaluate the efficacy of Rasona Haritaki Vati in the management of Dyslipidemia with special reference to Medoroga
Trial Snapshot
- Phase
- Phase 2/3
- Status
- Not yet recruiting
- Sponsor
- BANARAS HINDU UNIVERSITY
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- There will be significant improvement in lipid profile of patient.
Study Overview
Brief Summary
• Selection .Of .Patients:- .Following .a .comprehensive .history .taking, .clinical, .and laboratory .evaluations, .a .total .no. .of 80 .patients .with .clinical .symptoms .of .Dyslipidemia (Medoroga) .will .be .chosen .from .the .OPD .and .IPD .of .Kayachikitsa, .S. .S. .Hospital, .IMS, .B.H.U., .Varanasi .based .on .inclusion .and .exclusion .criteria.
• Duration .of .treatment: **.**3 .months .with .follow .up .at .30 .days .of . .interval.
• DOSE: Rasona Haritaki Vati - 500 mg BD
Atorvastatin- 40 mg OD
Grouping: Patient .will .be .selected .according .to .the .inclusion .or .exclusion .criteria .and .those .who .are .fulfilling .the .criteria .will .be .randomly .divided .into .two .groups (40 in each group). .
• Group .A: .- **.**Rasona .Haritaki Vati
• Group .B: .- .Atorvastatin
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Masking
- None
Eligibility Criteria
- Ages
- 21.00 Year(s) to 60.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •patients of age group between 21 to 60 years.
- •patient willing to enrolled in study.
Exclusion Criteria
- •age group less than 21 and more than 60 years of age.
- •patient not willing for trial.
Outcomes
Primary Outcomes
There will be significant improvement in lipid profile of patient.
Time Frame: 3 month
Secondary Outcomes
- Secondary outcome- Reduction in symptoms of Dyslipidemia and improve quality of life.
Investigators
NIHARIKA GAUTAM
Faculty of Ayurveda IMS BHU